CNMD Stock Overview
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$94.07|
|52 Week High||US$159.11|
|52 Week Low||US$87.24|
|1 Month Change||-18.63%|
|3 Month Change||-34.98%|
|1 Year Change||-33.28%|
|3 Year Change||9.93%|
|5 Year Change||84.67%|
|Change since IPO||6,955.25%|
Recent News & Updates
We Think CONMED (NYSE:CNMD) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Here's Why I Think CONMED (NYSE:CNMD) Might Deserve Your Attention Today
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
|CNMD||US Medical Equipment||US Market|
Return vs Industry: CNMD underperformed the US Medical Equipment industry which returned -23.7% over the past year.
Return vs Market: CNMD underperformed the US Market which returned -18.5% over the past year.
|CNMD Average Weekly Movement||6.9%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CNMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CNMD's weekly volatility (7%) has been stable over the past year.
About the Company
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands.
CONMED Fundamentals Summary
|CNMD fundamental statistics|
Is CNMD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNMD income statement (TTM)|
|Cost of Revenue||US$444.71m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.29|
|Net Profit Margin||6.63%|
How did CNMD perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Is CNMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CNMD?
Other financial metrics that can be useful for relative valuation.
|What is CNMD's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CNMD's PE Ratio compare to its peers?
|CNMD PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: CNMD is expensive based on its Price-To-Earnings Ratio (41.1x) compared to the peer average (32.8x).
Price to Earnings Ratio vs Industry
How does CNMD's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Earnings vs Industry: CNMD is expensive based on its Price-To-Earnings Ratio (41.1x) compared to the US Medical Equipment industry average (34.8x)
Price to Earnings Ratio vs Fair Ratio
What is CNMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||41.1x|
|Fair PE Ratio||40x|
Price-To-Earnings vs Fair Ratio: CNMD is expensive based on its Price-To-Earnings Ratio (41.1x) compared to the estimated Fair Price-To-Earnings Ratio (40x).
Share Price vs Fair Value
What is the Fair Price of CNMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CNMD ($94.07) is trading below our estimate of fair value ($133.78)
Significantly Below Fair Value: CNMD is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: CNMD is poor value based on its PEG Ratio (1.4x)
Discover undervalued companies
How is CONMED forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNMD's forecast earnings growth (29.9% per year) is above the savings rate (1.9%).
Earnings vs Market: CNMD's earnings (29.9% per year) are forecast to grow faster than the US market (14% per year).
High Growth Earnings: CNMD's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CNMD's revenue (9.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CNMD's revenue (9.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CNMD's Return on Equity is forecast to be low in 3 years time (16.6%).
Discover growth companies
How has CONMED performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNMD has high quality earnings.
Growing Profit Margin: CNMD's current net profit margins (6.6%) are higher than last year (1.5%).
Past Earnings Growth Analysis
Earnings Trend: CNMD's earnings have grown by 3.8% per year over the past 5 years.
Accelerating Growth: CNMD's earnings growth over the past year (403%) exceeds its 5-year average (3.8% per year).
Earnings vs Industry: CNMD earnings growth over the past year (403%) exceeded the Medical Equipment industry 12.9%.
Return on Equity
High ROE: CNMD's Return on Equity (8.6%) is considered low.
Discover strong past performing companies
How is CONMED's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CNMD's short term assets ($488.3M) exceed its short term liabilities ($187.6M).
Long Term Liabilities: CNMD's short term assets ($488.3M) do not cover its long term liabilities ($808.6M).
Debt to Equity History and Analysis
Debt Level: CNMD's net debt to equity ratio (87.4%) is considered high.
Reducing Debt: CNMD's debt to equity ratio has increased from 86.6% to 90.6% over the past 5 years.
Debt Coverage: CNMD's debt is not well covered by operating cash flow (12.5%).
Interest Coverage: CNMD's interest payments on its debt are well covered by EBIT (3.7x coverage).
Discover healthy companies
What is CONMED current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CNMD's dividend (0.85%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.57%).
High Dividend: CNMD's dividend (0.85%) is low compared to the top 25% of dividend payers in the US market (4.24%).
Stability and Growth of Payments
Stable Dividend: CNMD is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: CNMD is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: CNMD is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: CNMD is not paying a notable dividend for the US market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Curt Hartman (57 yo)
Mr. Curt R. Hartman has been Chairman of the Board at CONMED Corporation since May 21, 2020. Mr. Hartman has been the Chief Executive Officer and President of CONMED Corporation since November 09, 2014. Mr...
CEO Compensation Analysis
Compensation vs Market: Curt's total compensation ($USD9.37M) is above average for companies of similar size in the US market ($USD6.89M).
Compensation vs Earnings: Curt's compensation has increased by more than 20% in the past year.
Experienced Management: CNMD's management team is seasoned and experienced (7.4 years average tenure).
Experienced Board: CNMD's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CNMD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
CONMED Corporation's employee growth, exchange listings and data sources
- Name: CONMED Corporation
- Ticker: CNMD
- Exchange: NYSE
- Founded: 1970
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$2.778b
- Shares outstanding: 29.53m
- Website: https://www.conmed.com
Number of Employees
- CONMED Corporation
- 11311 Concept Boulevard
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.